Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.51 |
| ▸ | TTK | P33981 | 9/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018892 | 0.91 | TTK (0.50) | LRRK2TTKEGFRALKINSR | |
| SCHEMBL18018913 | 0.90 | EGFR (0.51) | LRRK2TTKEGFRALKINSR | |
| SCHEMBL18018861 | 0.87 | TTK (0.48) | LRRK2TTKEGFRALKINSR | |
| SCHEMBL18018866 | 0.87 | EGFR (0.49) | LRRK2TTKEGFRALKINSR | |
| SCHEMBL18018891 | 0.87 | TTK (0.48) | LRRK2TTKEGFRALKINSR | |
| SCHEMBL18018888 | 0.84 | ALK (0.49) | LRRK2TTKEGFRALKINSR | |
| SCHEMBL18018868 | 0.84 | EGFR (0.47) | LRRK2TTKEGFRALKINSR | |
| SCHEMBL18018863 | 0.84 | ALK (0.49) | TTKEGFRALKINSRIGF1R | |
| SCHEMBL18018890 | 0.83 | JAK3 (0.45) | TTKEGFRALKFES | |
| SCHEMBL18018918 | 0.83 | EGFR (0.47) | TTKEGFRALKFES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | LRRK2 1/4885TTK 1181/4885EGFR 2819/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | LRRK2 1/4885TTK 1181/4885EGFR 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.